The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes
Open Access
- 27 August 2016
- journal article
- research article
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 15 (1) , 141
Abstract
To determine whether 12 months of intensive medical therapy (IMT) improves HDL functionality parameters in subjects with type II diabetes (T2D). Retrospective, randomized, and controlled 12-month IMT intervention trial that enrolled 13-subjects with T2D (age 51- years, fasting glucose 147 mg/dL, body mass index [BMI] 36.5 kg/m2) and nine healthy control (46-years, fasting glucose 90 mg/dL, BMI 26.5 kg/m2). Subjects with T2D underwent IMT and HDL functionality measures (pro-inflammatory index of high-density lipoprotein (pHDL)), paraoxonase one (PON1), ceruloplasmin (Cp), and myeloperoxidase (MPO) activity were performed on samples at baseline and at 12-months following IMT. At baseline, pHDL index was significantly higher in subjects with T2D (p < 0.001) and apolipoprotein A-1 levels were significantly lower (p = 0.013) vs. controls. After 12-months, there was a trend for improved pHDL activity (p = 0.083), as indicated by intent-to-treat analysis, but when the non-adherent subject was omitted (per-protocol), significant attenuations in pHDL activity (p = 0.040) were noted; Δ pHDL activity at 12-months was associated with Δ weight (r = 0.62, p = 0.032) and Δ fasting glucose (r = 0.65, p = 0.022). Moreover, PON1 activity significantly improved (p < 0.001). The aforementioned occurred in association with improvements in inflammatory markers (i.e., C-reactive protein & tumor necrosis factor), hemoglobin A1C, fasting glucose, triglycerides, high-density lipoprotein levels and adipokines. IMT ameliorates pHDL index and significantly improves anti-oxidative function, as measured by PON1. Improvements in weight and fasting glucose mediated the decrease in pHDL index. Pharmacological aids and lifestyle modification are required to improve cardiovascular risk factors, subsequent mortality risk, and promote T2D remission. Application of either form of therapy alone may only have relatively miniscule effects on the aforementioned factors, in relation to the aggregate.Keywords
This publication has 47 references indexed in Scilit:
- Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complexJournal of Clinical Investigation, 2013
- Anti-inflammatory and Antioxidant Properties of HDLs Are Impaired in Type 2 DiabetesDiabetes, 2011
- Copper chelation by tetrathiomolybdate inhibits lipopolysaccharide-induced inflammatory responses in vivoAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Effect of Exercise Training on Plasma Levels and Functional Properties of High-Density Lipoprotein Cholesterol in the Metabolic SyndromeThe American Journal of Cardiology, 2011
- Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER DatabaseJournal of Lipid Research, 2010
- Modification of High Density Lipoprotein by Myeloperoxidase Generates a Pro-inflammatory ParticleJournal of Biological Chemistry, 2009
- Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetesJournal of Lipid Research, 2009
- Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factorsJournal of Applied Physiology, 2006
- Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-IJournal of Lipid Research, 2006
- Effects of the Neutral Lipid Content of High Density Lipoprotein on Apolipoprotein A-I Structure and Particle StabilityJournal of Biological Chemistry, 1995